25,113 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the second quarter, HoldingsChannel reports. The institutional investor bought 25,113 shares of the biopharmaceutical company’s stock, valued at approximately $932,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Agios Pharmaceuticals by 66.8% during the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after acquiring an additional 2,920 shares in the last quarter. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals during the 1st quarter valued at $40,000. Goldman Sachs Group Inc. boosted its stake in Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in Agios Pharmaceuticals during the 1st quarter worth $597,000.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AGIO has been the subject of several research analyst reports. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. HC Wainwright lifted their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, Truist Financial cut their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $41.25.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $34.40 on Wednesday. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The firm’s 50-day moving average is $35.54 and its 200-day moving average is $31.30. The company has a market cap of $2.05 billion, a P/E ratio of -4.91 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -5.87 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.